Feed RSS per la notifica dei nuovi comunicati pubblicati su informazione.it  

Tutte le Categorie

STMicroelectronics Attracts Linux Users to Free Embedded Development on STM32 Microcontrollers

Free high-productivity tools now available on Linux and Windows platforms, making STM32 an easy choice for fans of all major software OSes Geneva, February 9, 2016 - STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, has extended opportunities to design free of charge with its popular STM32 microcontrollers for Linux system users including professional engineers, academics, and hobbyists...
Thomson Reuters 09/02/2016 15:00

Harry Winston, Inc. Introduces the Countdown to a Cure Timepiece

Part of Harry Winston's timeless Midnight Collection, the men's version features a 42mm white gold case with a navy blue dial that is accented with a multicolor gradient, representing amfAR's Countdown to a Cure campaign colors that symbolize the fade of the disease from crisis to cure, while the complementing 32mm women's model is meticulously set with 12 brilliant-cut diamonds and 19 vivid gemstones, from rubies and sapphires to spessartite garnets.
PR Newswire 09/02/2016 15:00

CBRN Defence Market Report 2016-2026

Our new study reveals trends, market progress, and predicted revenues Overall world revenue for CBRN defence will reach $11,275m in 2016, our work calculates. Where is the CBRN defence market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.
PR Newswire 09/02/2016 15:00

3Doodler Start: World's First 3D Printing Pen Reimagined for Kids

3Doodler, the maker of the world's first 3D printing pen, has today announced the launch of the 3Doodler Start, available now for pre-order at http://www.the3doodler.com/start. Poised to take the kids' tech market by storm, the wireless, safe and child friendly pen is designed specifically for young creators aged 8-13.
PR Newswire 09/02/2016 15:00

Octapharma Selects IDBS' E-WorkBook 10

Octapharma GmbH ('Octapharma'), a leading biopharmaceuticals organization, has chosen E-WorkBook 10 from IDBS. The web-based electronic laboratory notebook (ELN) will be rolled out in Germany early this year to replace paper-based research and development (R&D) and protect valuable IP. Users will be able to search for information in real time and follow a specific researcher or experiment as part of the application, to boost collaboration and productivity.
PR Newswire 09/02/2016 15:00

Elsevier Launches Landmark Literature on India's Healthcare Reforms

Elsevier, a world-leading provider of scientific, technical and medical information products and services, recently announced the launch of Health Care Reforms in India: Making Up for the Lost Decade, an authoritative and incisive look at India's healthcare system from the perspective of Rajendra Pratap Gupta, an expert healthcare observer as well as an influential and respected voice on public policy, innovation and the economy.
PR Newswire 09/02/2016 14:58

OP-prime down to 0.45 per cent

OP Financial Group Press Release 9. February 2016 OP Financial Group will cut its OP-prime rate from 0.60% to 0.45%, effective as of 23 February 2016. The rate reduction is based on lower market interest rates. The OP-prime rate is a reference interest rate which is used to regulate OP Financial Group's borrowing and lending rates. The OP-prime rate was last changed in May 2015. FOR MORE INFORMATION, PLEASE CONTACT: Reijo Heiskanen, Chief Economist, tel...
Thomson Reuters 09/02/2016 14:23

Data From Prothena's Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology

Interim Results Previously Presented at Meetings of the American Society for Clinical Oncology and the European Hematology Association DUBLIN, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that interim data from its Phase 1/2 clinical study of NEOD001 in patients with AL Amyloidosis and persistent...
Thomson Reuters 09/02/2016 14:10